Dermata Therapeutics, Inc. DRMA 深 滬
等待開盤 11-26 09:30:00 美东时间
2.96
0.000
0.00%
華盛通- 最 高3.01
- 今 開2.8585
- 成交量 3.05万股
- 最 低 2.6001
- 昨 收 2.96
- 總市值 201.75万
- 52周最高 23.70
- 市盈率 靜 --
- 換手率 4.48%
- 52周最低 2.36
- 委 比 66.67%
- 總股本 68.16万
- 歷史最高 16680.00
- 量 比 0.36
- 振 幅 13.85%
- 歷史最低 2.6001
- 每 手 1
- 風險率 3.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock rose 10.2% to $2.8 during Wedn...
11-20 05:07
Dermata Therapeutics Q3 EPS $(1.65) Misses $(1.59) Estimate
Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(1.59) by 3.77 percent. This is a 91.92 percent increase over losses of $(20.41) per share
11-15 05:07
Dermata Therapeutics Announces Australian Patent Office Accept Patent Application For Spongilla Technology Combination As Method For Treating Acne
- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne -- Dermata expects to launch a new once-weekly, Over-the-Counter (OTC)
10-02 20:02
Dermata Therapeutics Presents Promising Phase 3 Trial Results
Dermata Therapeutics ( ($DRMA) ) has provided an update. On September 17, 2025,...
09-17 18:29
Dermata Therapeutics Announces Strategic Pivot To Prioritize Development And Distribution Of OTC Pharmaceutical Dermatology Focused Products
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced a bold strategic pivot to prioritize the development and
09-10 20:09
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 21.6% to $0.52 during Wedne...
09-04 05:06
Dermata Therapeutics Regains Nasdaq Compliance by August 2025
The latest announcement is out from Dermata Therapeutics ( ($DRMA) ). On May 14...
08-26 05:32
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $10
Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target from $30 to $10.
08-22 00:32
Australian Patent Office Dermata Therapeutics Patent Application For DMT410 Program For Hyperhidrosis Titled "Compositions for the treatment of skin conditions," (Australian Patent No. 2109284621)
- This is the Company's second granted patent for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -- The Company recently entered into a Clinical Trial Collaboration
07-08 20:11
